A process for refolding recombinant chymotrypsinogen produced from a prokaryote host cell comprising: (a) providing the recombinant chymotrypsinogen from inclusion bodies isolated from the prokaryote host cell at a concentration of 5 to 15 g/L in a solubilization solution comprising a chaotropic agent, a buffer agent, and a low molecular weight reducing agent in the absence of a low molecular weight oxidizing agent at a pH of the pI of chymotrypsinogen or greater, wherein the solubilization solution does not include a low molecular weight oxidizing agent to provide a redox pair comprising the low molecular weight reducing agent and a low molecular weight oxidizing agent, wherein: (i) the low molecular weight reducing agent in the solubilization solution comprising the recombinant chymotrypsinogen is at a concentration sufficient to provide 1 to 15 SH residues of the low molecular weight reducing agent per cysteine residue of the recombinant chymotrypsinogen, (ii) the chaotropic agent is urea or guanidinium chloride and wherein the chaotropic agent is at a concentration from 6 to 8.5 M; and (b) infusing the solubilization solution comprising the recombinant chymotrypsin over time into a diluent comprising the chaotropic agent, buffer agent, and low molecular weight reducing agent in the absence of a low molecular weight oxidizing agent to provide a refold solution comprising the recombinant chymotrypsinogen at a concentration of 1 g/L to 5 g/L or of 1.5 g/L, the chaotropic agent at a concentration that is 1.4 to 1.8 M, and the low molecular weight reducing agent at a concentration sufficient to provide 1 to 30 SH residues of the low molecular reducing agent per cysteine residue of the recombinant chymotrypsinogen, and (c) incubating the refold solution for a time sufficient for the recombinant chymotrypsinogen to refold into a conformation characteristic of native chymotrypsinogen and form the disulfide bonds characteristic of native chymotrypsinogen, wherein the refold solution does not include a low molecular weight oxidizing agent to provide a redox pair comprising the low molecular weight reducing agent and a low molecular weight oxidizing agent. (a) providing the recombinant chymotrypsinogen from inclusion bodies isolated from the prokaryote host cell at a concentration of 5 to 15 g/L in a solubilization solution comprising a chaotropic agent, a buffer agent, and a low molecular weight reducing agent in the absence of a low molecular weight oxidizing agent at a pH of the pI of chymotrypsinogen or greater, wherein the solubilization solution does not include a low molecular weight oxidizing agent to provide a redox pair comprising the low molecular weight reducing agent and a low molecular weight oxidizing agent, wherein: (i) the low molecular weight reducing agent in the solubilization solution comprising the recombinant chymotrypsinogen is at a concentration sufficient to provide 1 to 15 SH residues of the low molecular weight reducing agent per cysteine residue of the recombinant chymotrypsinogen, (ii) the chaotropic agent is urea or guanidinium chloride and wherein the chaotropic agent is at a concentration from 6 to 8.5 M; and (i) the low molecular weight reducing agent in the solubilization solution comprising the recombinant chymotrypsinogen is at a concentration sufficient to provide 1 to 15 SH residues of the low molecular weight reducing agent per cysteine residue of the recombinant chymotrypsinogen, (ii) the chaotropic agent is urea or guanidinium chloride and wherein the chaotropic agent is at a concentration from 6 to 8.5 M; and (b) infusing the solubilization solution comprising the recombinant chymotrypsin over time into a diluent comprising the chaotropic agent, buffer agent, and low molecular weight reducing agent in the absence of a low molecular weight oxidizing agent to provide a refold solution comprising the recombinant chymotrypsinogen at a concentration of 1 g/L to 5 g/L or of 1.5 g/L, the chaotropic agent at a concentration that is 1.4 to 1.8 M, and the low molecular weight reducing agent at a concentration sufficient to provide 1 to 30 SH residues of the low molecular reducing agent per cysteine residue of the recombinant chymotrypsinogen, and (c) incubating the refold solution for a time sufficient for the recombinant chymotrypsinogen to refold into a conformation characteristic of native chymotrypsinogen and form the disulfide bonds characteristic of native chymotrypsinogen, wherein the refold solution does not include a low molecular weight oxidizing agent to provide a redox pair comprising the low molecular weight reducing agent and a low molecular weight oxidizing agent.